via National Cancer Institute
A team of University of Chicago chemists and biologists developed a tiny device made out of DNA intended to locate tumor cells and force them to reveal themselves to patrolling immune cells.
Early tests at UChicago show promise for treating resistant tumors with this unique approach
One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells. A team of University of Chicago chemists and biologists developed a tiny device that can locate tumor cells and force them to reveal themselves to patrolling immune cells. In tests with mice, this resulted in tumor regression.
“When it comes to drug delivery, the problem, as molecular biologist Inder Verma put it, is delivery, delivery, and delivery,” explained Yamuna Krishnan, a professor in the Department of Chemistry and an author of the study. “These DNA nanodevices now make drug delivery hyperspecific, allowing us to think of ways to treat cancer without killing the cell that the therapeutic is delivered to.”
The focus of these nanodevices is a particular type of cell known as tumor-associated macrophages, or TAMs. Macrophages are a type of immune cell that normally is supposed to recognize and remove microbes, cellular debris, and other foreign substances from cells; but if something goes wrong with them, they can become a key part of cancerous tumors. TAMs can comprise up to 50% of tumor mass in triple-negative breast cancer.
However, “despite the high abundance of TAMs in solid tumors, mechanisms underlying their impact on tumor development and therapeutic strategies to target them are incompletely understood,” said study co-author Lev Becker, associate professor in the Ben May Department for Cancer Research.
The importance of these TAMs goes back to how the immune system recognizes cancerous cells. There is a subpopulation of immune cells called CD8+ T cells that are critical in recognizing and killing cancerous cells. These CD8+ T cells can be activated against threats by binding to molecular structures called “antigens” on the surface of cancerous macrophages. This strategy goes awry, however, when TAMs don’t present antigens, so there is nothing for the T-cells to recognize.
Becker’s group found that TAMs harbored a high level of a kind of enzyme called cysteine proteases. They knew these particular enzymes live in lysosomes, which work as the “stomach” of the cell, so Becker’s insight was that they might be “over-digesting” tumor antigens –thereby concealing cancerous cells from patrolling CD8+ T cells.
To test this idea, Becker’s group needed to prove that the problem really did lie in the lysosomes eating away at the antigens. So they used mice whose macrophages lacked a protein that regulates lysosomal enzyme levels and activity. They found that indeed, the lysosomes in the TAMs of these mice weren’t destroying antigens as much. This ultimately allowed CD8+ T cells to “see” and attack the tumor.
Next, they needed to figure out a way to target this process therapeutically.
Meanwhile, Krishnan, an expert in DNA nanotechnology, had recently developed the expertise to send tiny nanodevices made out of DNA directly to the lysosomes of specific immune cells in model organisms such as worms and zebrafish. The two labs teamed up to overcome this challenge.
Kasturi Chakraborty, a former grad student of the Krishnan lab and now a postdoctoral scholar in Becker’s lab, developed a tiny DNA nanodevice that delivered a cysteine protease inhibitor. When Chang Cui, a graduate student in the Becker lab, injected it into a mouse with a tumor, this nanodevice preferentially targeted lysosomes inside TAMs, where it stopped the enzymes from destroying antigens—rendering them once again “visible” to patrolling immune cells.
Combining this DNA nanodevice with frontline chemotherapy led to sustained tumor regression in a triple-negative-breast-cancer model in tests with mice. This outcome was exciting because this type of cancer is particularly difficult to treat.
It’s also a fundamentally different approach from the standard way that researchers think about treating cancer: “When we target a drug, success usually means you have killed the cell you wanted to target,” said Krishnan. “However, in our approach, our intent was not to kill the target cells, but rather reprogram them and change their character. Once the nanodevice flips the switch in a TAM, natural immunity takes care of the rest.”
The researchers hope that this new organelle-specific delivery using DNA nanodevices is the next generation of drug targeting.
It could even go beyond cancer, because specific delivery to macrophages could impact a broad range of diseases where immunity has gone awry, the scientists said.
“You wouldn’t see this work in just a chemistry lab or just an immunology lab,” said Chakraborty. “At UChicago, chemists and biologists are in the same building, so there is an easy flow of interactions and the environment really encourages interdisciplinary science.”
Original Article: Could tiny devices made out of DNA treat cancer?
More from: University of Chicago
The Latest on: DNA nanodevices
- The emergence of form: New study expands horizons for DNA nanotechnologyon June 29, 2022 at 10:45 am
DNA proves to be an ideal material with which ... forms to be added to the ever-growing plethora of nanostructures and nanodevices serving a broad range of applications in electronics, imaging ...
- Nanotoxicity: A Key Obstacle to Clinical Translation of siRNA-Based Nanomedicineon June 28, 2022 at 5:00 pm
Moderate level of ROS causes DNA damages and lipid peroxidation ... nanoparticle surface area and impurities in the nanodevices Nanocarriers overloading the lysosomes, for example, owing to ...
- Global Optical Genome Mapping Market, By Product, By Application, By End User, By Region, Competition Forecast & Opportunities, 2027on June 20, 2022 at 1:45 am
Optical genome mapping represents an emerging technology that utilizes labeled and high molecular weight DNA that is subsequently electrophoresed to nanochannels and linearized for imaging. Optical ...
- Nanodevices Self-Assemble Using DNAon June 7, 2022 at 5:01 pm
Though many of those efforts have used carbon nanotubes, Harvard University's Wyss Institute for Biologically Inspired Engineering has harnessed DNA to create self-assembling nanodevices. The emerging ...
- Biotechnologies for Gene Therapy: RNA, CRISPR, Nanobots, and Preclinical Applicationson June 2, 2022 at 5:00 pm
It also features innovations of the delivery methods for nucleic acids ranging from nanodevices made from DNA and pseudo amino acids to viral vectors. This is an ideal book for academics, clinicians, ...
- DNA Nanodevices Sneak Past Mouse Immune Systemson May 15, 2022 at 5:00 pm
(Courtesy Steven Perrault/Harvard's Wyss Institute) Scientists at Harvard's Wyss Institute for Biologically Inspired Engineering have built the first DNA nanodevices that survive the body's immune ...
- Researchers Use Engineered DNA to Develop Programmable Glueon May 11, 2022 at 5:00 pm
Then, those methods had been extended from self-assembling, two-dimensional, engineered DNA nanodevices to self-assembling, three-dimensional, engineered DNA bricks. Now, the research team has used ...
- A Nanoscale Voltmeter Reveals Biology Hidden in Plain Sighton April 13, 2021 at 9:18 am
where she pioneered the deployment of DNA nanodevices for quantitative chemical imaging in living systems. She received the Shanti Swarup Bhatnagar Award for Chemical Sciences and the Infosys ...
- Robotics on the nanoscaleon February 25, 2019 at 8:50 pm
Nanoscale robots can be programmed to walk a DNA origami track ... assemblies may be made in nanofactories, and in vivo nanodevices that kill cancer cells or repair tissues may be a mainstay ...
via Bing News
The Latest on: DNA nanodevices
via Google News